Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344293 | 0.88 | KMO (0.46) | DHODHKMO | |
| SCHEMBL3343333 | 0.86 | SCN9A (0.41) | SLC6A4SLC6A3KMOSCN9ATGFBR1 | |
| SCHEMBL3340790 | 0.84 | ALPL (0.53) | ALPLSLC6A4SLC6A3MAPK14DHODH | |
| SCHEMBL3341309 | 0.81 | CHRNA7 (0.42) | SLC6A4SLC6A3CTSAKMOSCN9A | |
| SCHEMBL3342017 | 0.80 | SYK (0.43) | MAPT | |
| SCHEMBL3344080 | 0.79 | FEN1 (0.39) | DHODHKMO | |
| SCHEMBL3342890 | 0.76 | SCN9A (0.43) | DHODHSCN9AMAPTTGFBR1 | |
| SCHEMBL3342056 | 0.75 | NPC1 (0.41) | DHODHSCN9A | |
| SCHEMBL3341965 | 0.75 | MAPK8 (0.43) | SLC6A4SLC6A3DHODHSCN9A | |
| SCHEMBL3341299 | 0.74 | ALDH1A1 (0.47) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| WO-2008031500-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | PPARA, PPARD, PPARG | ALPL 2813/4885SLC6A4 1307/4885SLC6A3 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.